<DOC>
	<DOCNO>NCT02877303</DOCNO>
	<brief_summary>The goal clinical research study learn Blinacyto ( blinatumomab ) , give Hyper-CVAD , help control newly diagnose B-Cell Lineage ALL . The safety drug also study .</brief_summary>
	<brief_title>Hyper-CVAD Regimen Sequential Combination With Blinatumomab Frontline Therapy Adults With B-Cell Lineage Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>Study Drug Administration : Each study cycle 6 week . If find eligible take part study , receive CVC already one . A CVC sterile flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form procedure . Hyper-CVAD ( Cycles 1 3 ) : During Cycles 1 3 also receive follow drug : - On Days 1-3 , receive cyclophosphamide 2 time day vein 3 hour . - On Days 1-3 , receive mesna vein non-stop help prevent side effect . The mesna infusion start one hour prior end 12 hour last dose cyclophosphamide . - On Days 1-4 11-14 , receive dexamethasone 1 time day mouth vein 30 minute . - On Days 1 11 , doctor think best interest , may receive ofatumumab rituximab vein 4 6 hour . The study doctor decide long infusion last . - On Day 2 , receive methotrexate lumbar puncture . - On Day 4 , receive doxorubicin vein non-stop 1 day CVC . - On Days 4 11 , receive vincristine vein 15 minute . - On Day 7 , receive cytarabine lumbar puncture . During Cycles 2 4 , also receive follow drug : - On Day 1 , receive methotrexate vein 24 hour . - On Days 1 8 , doctor think best interest , may receive ofatumumab rituximab vein 4 6 hour . The study doctor decide long infusion last . - On Days 2 3 , receive cytarabine vein 2 time day 2 hour . - On Day 5 , receive cytarabine lumbar puncture . - On Day 8 , receive methotrexate lumbar puncture . You may receive filgrastim pegfilgrastim injection skin end every cycle help raise blood cell count . If doctor think need help reduce risk side effect , may receive leucovorin vein 4 time day 8 dos , begin 12 hour methotrexate dose end . You may give drug help prevent side effect . The study staff tell drug , give , possible risk . After finish receive Hyper-CVAD , receive blinatumomab nonstop Weeks 1-4 every 6 week Cycles 5-8 . You receive blinatumomab peripherally inserted central catheter . This allow receive drug constantly long period time . Your doctor explain procedure detail , require sign separate consent form procedure . During first cycle blinatumomab , infusion start hospital . You hospital 9 night monitor side effect . Your doctor decide leave hospital . Blinatumomab deliver small pump , carry whole time receive drug . You give shoulder belt bag hold pump infusion bag . You able wear regular clothes , walk around , perform daily living activity . You give instruction take shower activity . However , line must keep free infection connect pump , thing , go swim . The study staff give information activity receive drug . You need come MD Anderson infusion bag change every 48 hour . The study staff let know need return clinic . Maintenance Therapy : After receive 4 cycle blinatumomab , may able receive maintenance therapy 12 month . During Maintenance Therapy , receive follow drug : - Every day , take 6-mercaptopurine mouth 3 time . - Every week , take pill methotrexate . - Every month , receive vincristine vein 1 time 15 minute . - On Days 1-5 every month , take prednisone mouth . Study Visits : At begin every cycle , monthly Maintenance Phase , physical exam . One ( 1 ) time week Cycles 1-8 , every month Maintenance Phase , blood ( 2-3 teaspoon ) draw routine test . On Day 14 ( +/- 3 day ) Cycle 1 , bone marrow biopsy/aspiration check status disease This do every week disease appear go away . If disease appear completely go away , may need another bone marrow biopsy/aspiration finish receive Hyper CVAD and/or begin receive blinatumomab . Within 14 day receive blinatumomab , neurological exam . If disease appear completely go away , Days 28 42 ( +/- 7 day ) Cycle 5 , bone marrow biopsy/aspiration check status disease . This do every cycle receive blinatumomab , every 4 month . If disease appear completely go away , bone marrow biopsy/aspiration every 4 month begin receive blinatumomab . At point doctor think need , PET-CT scan x-ray check status disease . Length Study : You receive 4 cycle blinatumomab chemotherapy , follow 1 year maintenance therapy . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Follow-Up : You call study staff ask health 1 time month 24 month participant enrol study . These call last 5-10 minute . This investigational study . Blinatumomab FDA approve commercially available treatment ALL treat come back . It investigational use drug first option treatment disease . Hyper-CVAD FDA approve commercially available treatment ALL . The study doctor explain study drug design work . Up 60 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Blinatumomab</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>1 . Patients least 14 year age newly diagnose , previously untreated Blineage ALL , achieve CR one course induction chemotherapy . 2 . Failure one induction course chemotherapy ( patient analyze separately ) . 3 . Performance status 03 4 . Adequate organ function creatinine less equal 2.0 mg/dL ( unless consider tumor relate ) , bilirubin less equal 2.0 mg/dL ( unless consider tumor relate ) . 5 . Adequate cardiac function assess history physical examination . 6 . No active coexisting malignancy life expectancy le 12 month . 1 . Pregnant nursing woman . 2 . Known HIVpositive 3 . Phpositive ALL 4 . Active uncontrolled disease/infection judge treat physician 5 . Unable unwilling sign consent form 6 . Subjects current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) 7 . History presence clinically relevant CNS pathology epilepsy , childhood adult seizure , paresis , aphasia , stroke , severe brain injury , dementia , Parkinson 's disease , cerebellar disease , organic brain syndrome , psychosis . 8 . Chronic current infectious disease require systemic antibiotic , antifungal , antiviral treatment , limited , chronic renal infection , chronic chest infection bronchiectasis , tuberculosis active Hepatitis C. 9 . Current autoimmune disease history autoimmune disease potential CNS involvement . Autoimmune disease possible CNS consequences/manifestations epilepsy , paresis , aphasia , stroke , dementia , Parkinson 's disease , cerebellar disease , psychosis . 10 . Subjects weigh less 45 kg exclude . 11 . Patients candidate , tolerate intensive chemotherapy blinatumomab , exclude .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Newly diagnose B-Cell Lineage Acute lymphoblastic leukemia</keyword>
	<keyword>Blinatumomab</keyword>
	<keyword>Blincyto</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Pegfilgrastim</keyword>
	<keyword>Neulasta</keyword>
	<keyword>PEG-G-CSF</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Revimmune</keyword>
	<keyword>Clafen</keyword>
	<keyword>Mesna</keyword>
	<keyword>Mesnex</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Ofatumumab</keyword>
	<keyword>Arzerra</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>MTX</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Doxorubicin Hydrochloride</keyword>
	<keyword>Adriamycin PFS</keyword>
	<keyword>Adriamycin RDF</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Rubex</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Oncovin</keyword>
	<keyword>Vincasar PFS</keyword>
	<keyword>Vincristine Sulfate</keyword>
	<keyword>LCR</keyword>
	<keyword>VCR</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>ARA-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine Arabinosine Hydrochloride</keyword>
	<keyword>Arabino Sylcytosine</keyword>
	<keyword>Cytosine Arabinoside</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Citrovorum</keyword>
	<keyword>Wellcovorin</keyword>
	<keyword>6-Mercaptopurine</keyword>
	<keyword>Mercaptopurine</keyword>
	<keyword>Purinethol</keyword>
	<keyword>6-MP</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Deltasone</keyword>
	<keyword>Orasone</keyword>
	<keyword>Prednicen-M</keyword>
</DOC>